SCHEMBL1807602

SCHEMBL1807602

N#Cc1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
ENPP2 Q13822 1/20 0.39
SIRT2 Q8IXJ6 12/20 0.35
TSHR P16473 2/20 0.33
NR1I2 O75469 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
TBXA2R P21731 2/20 0.33
CCKBR P32239 2/20 0.33
OPRK1 P41145 2/20 0.33
SLC6A3 Q01959 2/20 0.33
KCNH2 Q12809 2/20 0.33
NR1H4 Q96RI1 2/20 0.33
MEN1 O00255 1/20 0.33
SLC22A1 O15245 1/20 0.33
KCNN4 O15554 1/20 0.33
GMNN O75496 1/20 0.33
USP2 O75604 1/20 0.33
TRPM2 O94759 1/20 0.33
ABCB11 O95342 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3743240 0.83 CYP11B1 (0.43) CYP11B1CYP11B2ENPP2SIRT2TSHR
SCHEMBL19029720 0.81 CYP11B1 (0.42) CYP11B1CYP11B2ENPP2SIRT2TSHR
SCHEMBL24337277 0.79 CTSS (0.47) CYP11B1CYP11B2ENPP2SIRT2ADORA2A
SCHEMBL19028866 0.78 CYP11B1 (0.39) CYP11B1CYP11B2ENPP2SIRT2TSHR
SCHEMBL8497831 0.76 CYP11B1 (0.41) CYP11B1CYP11B2ENPP2SIRT2TSHR
SCHEMBL4009153 0.76 SIRT2 (0.43) CYP11B1CYP11B2ENPP2SIRT2MEN1
SCHEMBL5857986 0.75 ENPP2 (0.42) CYP11B1CYP11B2ENPP2SIRT2CYP19A1
SCHEMBL8174813 0.75 MAOB (0.40) MEN1LMNACYP19A1MAOBOPRM1
SCHEMBL9547333 0.74 CYP11B1 (0.39) CYP11B1CYP11B2ENPP2SIRT2TSHR
SCHEMBL6553669 0.74 CYP11B1 (0.39) CYP11B1CYP11B2ENPP2SIRT2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 EP disclosed
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2017-09-14 US disclosed
CN-102596910-B Androgen receptor modulating compounds ORION CORP. (FI) 2015-11-25 CN disclosed
CN-105061313-A Androgen receptor modulating compounds ORION CORP 2015-11-18 CN disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 EP disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 CN disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG CYP11B1 23/4885CYP11B2 19/4885ENPP2 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.